WHOCC
Postal address:
WHO Collaborating Centre for Drug Statistics Methodology
Norwegian Institute of Public Health
P.O.Box 4404 Nydalen
0403 Oslo
Norway

Visiting/delivery address:
Marcus Thranes gate 6
0473 Oslo
Norway

Tel:  +47 21 07 81 60
E-mail:
 
Copyright/Disclaimer

List of new ATC codes decided at the latest meetings of the WHO International Working Group for Drug Statistics Methodology. Comments or objections to the ATC codes should be forwarded to the WHO Collaborating Centre for Drug Statistics Methodology within the deadline. If no objections are received, the new ATC codeswill be considered final and included in the ATC/DDD Index. The year of implementation in the ATC/DDD Index is given in the list.

ATC codeATC level name (INN/generic name)Deadline for objection to temporary code Implementation in the ATC/DDD index
A06AH05naldemedine01.02.20182019
A07XA05telotristat01.02.20182019
A07XA06crofelemer 01.02.20182019
A10BD23metformin and ertugliflozin01.02.20182019
A10BD24sitagliptin and ertugliflozin01.02.20182019
A10BK04ertugliflozin01.02.20182019
A10BK05ipragliflozin01.02.20182019
B01AX07caplacizumab01.02.20182019
B02BX07lusutrombopag01.02.20182019
B03XA05roxadustat01.02.20182019
B06AC05lanadelumab01.02.20182019
C02KX52ambrisentan and tadalafil01.02.20182019
C09DX05valsarten and nebivolol01.02.20182019
D04AX01doxepin01.02.20182019
D11AH06crisaborole 01.02.20182019
G01AX17dapivirine01.02.20182019
G02BB02vaginal ring with progestogen01.02.20182019
G03AA17medroxyprogesterone and estradiol01.02.20182019
G03AB09norgestimate and ethinylestradiol01.02.20182019
G04CX04fexapotide01.02.20182019
J01AA13eravacycline01.02.20182019
J01DD18cefteram01.02.20182019
J01DH06tebipenem pivoxil01.02.20182019
J01DH52meropenem and vaborbactam01.02.20182019
J01MA22tosufloxacin01.02.20182019
J01MA23delafloxacin01.02.20182019
J04AM07rifampicin, ethambutol and isoniazid01.02.20182019
J04AM08isoniazid, sulfamethoxazole, trimethoprim and pyridoxine01.02.20182019
J05AH03peramivir01.02.20182019
J05AP57glecaprevir and pibrentasvir 01.02.20182019
J05AR23atazanavir and ritonavir01.02.20182019
J05AX17enisamium iodide01.02.20182019
J05AX18letermovir01.02.20182019
J05AX19tilorone01.02.20182019
J05AX21imidazolyl ethanamide pentandioic acid01.02.20182019
J05AX22kagocel01.02.20182019
L01AD08uramustine01.02.20182019
L01BC09floxuridine01.02.20182019
L01XC31avelumab01.02.20182019
L01XC32atezolizumab01.02.20182019
L01XE44lorlatinib01.02.20182019
L01XE45neratinib01.02.20182019
L01XE46encorafenib01.02.20182019
L01XE47dacomitinib01.02.20182019
L01XE48icotinib01.02.20182019
L01XX58epacadostat01.02.20182019
L01XX59enasidenib01.02.20182019
L01XY01cytarabine and daunorubicin01.02.20182019
L04AA38ozanimod01.02.20182019
L04AA39emapalumab01.02.20182019
L04AA40cladribine 1)01.02.20182019
L04AC17tildrakizumab01.02.20182019
M05BB09ibandronic acid and colecalciferol01.02.20182019
N02CX08galcanezumab01.02.20182019
N07XX12patisiran01.02.20182019
N07XX13valbenazine01.02.20182019
R03CC63clenbuterol and ambroxol01.02.20182019
S01XA26riboflavin01.02.20182019
V04CX01indocyanine green01.02.20182019
1) Oral formulations indicated for multiple sclerosis. Parenteral formulations are classified in L01BB04.

Last updated: 2017-11-28